Revelation Other Current Liab from 2010 to 2024

REVBW Stock  USD 0.01  0.0001  0.81%   
Revelation Biosciences Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities will likely drop to about 2.2 M in 2024. During the period from 2010 to 2024, Revelation Biosciences Other Current Liabilities regression line of quarterly data had mean square error of 1.1 T and geometric mean of  107,603. View All Fundamentals
 
Other Current Liabilities  
First Reported
2010-12-31
Previous Quarter
4.2 M
Current Value
2.2 M
Quarterly Volatility
1.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Revelation Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Revelation Biosciences' main balance sheet or income statement drivers, such as Other Operating Expenses of 7 M, Total Operating Expenses of 7 M or Total Other Income Expense Net of 9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.54. Revelation financial statements analysis is a perfect complement when working with Revelation Biosciences Valuation or Volatility modules.
  
Check out the analysis of Revelation Biosciences Correlation against competitors.
For more information on how to buy Revelation Stock please use our How to Invest in Revelation Biosciences guide.

Latest Revelation Biosciences' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Revelation Biosciences over the last few years. It is Revelation Biosciences' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Revelation Biosciences' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Revelation Other Current Liab Regression Statistics

Arithmetic Mean829,087
Geometric Mean107,603
Coefficient Of Variation176.14
Mean Deviation1,135,198
Median26,309
Standard Deviation1,460,354
Sample Variance2.1T
Range4.2M
R-Value0.73
Mean Square Error1.1T
R-Squared0.53
Significance0
Slope237,853
Total Sum of Squares29.9T

Revelation Other Current Liab History

20242.2 M
20234.2 M
20223.9 M
20211.5 M
2020342.9 K

About Revelation Biosciences Financial Statements

Revelation Biosciences investors use historical fundamental indicators, such as Revelation Biosciences' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Revelation Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities4.2 M2.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Revelation Stock Analysis

When running Revelation Biosciences' price analysis, check to measure Revelation Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revelation Biosciences is operating at the current time. Most of Revelation Biosciences' value examination focuses on studying past and present price action to predict the probability of Revelation Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revelation Biosciences' price. Additionally, you may evaluate how the addition of Revelation Biosciences to your portfolios can decrease your overall portfolio volatility.